Jacob Laubach, MD

Articles

The real promise of improving patient outcomes in IgD and IgE multiple myeloma lies in multi-drug combinations, next-generation agents, and immunotherapy.

IgD and IgE Variants of Myeloma: Valuable Insights and Therapeutic Opportunities

Monoclonal gammopathy of undetermined significance (MGUS) is the most prevalent of the plasma cell dyscrasias and is characterized by a low level of production of serum monoclonal (M) protein (classically less than 3 g/dL).

MGUS and Smoldering Myeloma: the Most Prevalent of Plasma Cell Dyscrasias

Responses to treatment of relapsed and refractory multiple myeloma are characteristically short, and median survival is as brief as 6 months. Although prognostic factors in the context of relapsed and refractory disease require further characterization, high-risk patients include those with certain cytogenetic abnormalities, high β2-microglobulin, and low serum albumin.

Tailoring Treatment for Multiple Myeloma Patients With Relapsed and Refractory Disease

In this issue of ONCOLOGY, Dingli and Rajkumar provide an expert review of novel therapies in multiple myeloma. As their work underscores, the rapid clinical development of the immunomodulatory drugs-specifically thalidomide (Thalomid) and lenalidomide (Revlimid), and the proteasome inhibitor bor­tezomib (Velcade)-has changed the therapeutic landscape of this disease, resulting in significant improvements in patient outcomes.[1]

Author | Jacob Laubach, MD

Articles

New content coming soon, please check back later.